Clinical	clinical	O	O
evaluation	evaluation	O	O
on	on	O	O
combined	combined	O	O
administration	administration	O	O
of	of	O	O
oral	oral	O	O
prostacyclin	prostacyclin	O	O
analogue	analogue	O	O
beraprost	beraprost	O	O
and	and	O	O
phosphodiesterase	phosphodiesterase	O	O
inhibitor	inhibitor	O	O
cilostazol	cilostazol	O	O
.	.	O	O

Among	among	O	O
various	various	O	O
oral	oral	O	O
antiplatelets	antiplatelets	O	O
,	,	O	O
a	a	O	O
combination	combination	O	O
of	of	O	O
a	a	O	O
novel	novel	O	O
prostacyclin	prostacyclin	O	O
analogue	analogue	O	O
beraprost	beraprost	O	O
(	(	O	O
BPT	bpt	O	O
)	)	O	O
and	and	O	O
a	a	O	O
potent	potent	O	O
phosphodiesterase	phosphodiesterase	O	O
inhibitor	inhibitor	O	O
cilostazol	cilostazol	O	O
(	(	O	O
CLZ	clz	O	O
)	)	O	O
may	may	O	O
result	result	O	O
in	in	O	O
untoward	untoward	O	O
clinical	clinical	O	O
effects	effects	O	O
due	due	O	O
to	to	O	O
possible	possible	O	O
synergistic	synergistic	O	O
elevation	elevation	O	O
of	of	O	O
intracellular	intracellular	O	O
cAMP	camp	O	O
(	(	O	O
cyclic	cyclic	O	O
adenosine	adenosine	S_chemical	O
3',5'-monophosphate	3',5'-monophosphate	O	O
)	)	O	O
.	.	O	O

Thereby	thereby	O	O
,	,	O	O
a	a	O	O
clinical	clinical	O	O
study	study	O	O
of	of	O	O
the	the	O	O
combined	combined	O	O
administration	administration	O	O
of	of	O	O
the	the	O	O
two	two	O	O
agents	agents	O	O
was	was	O	O
attempted	attempted	O	O
.	.	O	O

Twelve	twelve	O	O
healthy	healthy	O	O
volunteers	volunteers	O	O
were	were	O	O
assigned	assigned	O	O
to	to	O	O
take	take	O	O
BPT/CLZ	bpt/clz	O	O
in	in	O	O
the	the	O	O
following	following	O	O
schedule	schedule	O	O
;	;	O	O
BPT	bpt	O	O
:	:	O	O
40	40	O	O
micrograms	micrograms	O	O
at	at	O	O
day	day	O	O
1	1	O	O
and	and	O	O
120	120	O	O
micrograms	micrograms	O	O
t.i.d	t.i.d	O	O
.	.	O	O
from	from	O	O
day	day	O	O
7	7	O	O
to	to	O	O
14	14	O	O
,	,	O	O
CLZ	clz	O	O
:	:	O	O
200	200	O	O
mg	mg	O	O
t.i.d	t.i.d	O	O
.	.	O	O
from	from	O	O
day	day	O	O
3	3	O	O
to	to	O	O
14	14	O	O
.	.	O	O

At	at	O	O
various	various	O	O
time	time	O	O
intervals	intervals	O	O
,	,	O	O
physical	physical	O	O
examination	examination	O	O
and	and	O	O
blood	blood	O	O
collection	collection	O	O
for	for	O	O
ex	ex	O	O
vivo	vivo	O	O
platelet	platelet	O	B_disease
aggregation	aggregation	O	I_disease
and	and	O	O
determination	determination	O	O
of	of	O	O
intraplatelet	intraplatelet	O	O
cAMP	camp	O	O
were	were	O	O
performed	performed	O	O
.	.	O	O

Throughout	throughout	O	O
the	the	O	O
observation	observation	O	O
period	period	O	O
,	,	O	O
no	no	O	O
significant	significant	O	O
alteration	alteration	O	O
in	in	O	O
vital	vital	O	O
signs	signs	O	O
was	was	O	O
observed	observed	O	O
.	.	O	O

Seven	seven	O	O
out	out	O	O
of	of	O	O
12	12	O	O
subjects	subjects	O	O
experienced	experienced	O	O
headache	headache	O	S_disease
of	of	O	O
a	a	O	O
short	short	O	O
duration	duration	O	O
accompanying	accompanying	O	O
facial	facial	O	O
flush	flush	O	O
in	in	O	O
one	one	O	O
and	and	O	O
nausea	nausea	O	S_disease
in	in	O	O
one	one	O	O
,	,	O	O
especially	especially	O	O
after	after	O	O
ingestion	ingestion	O	O
of	of	O	O
CLZ	clz	O	O
.	.	O	O

All	all	O	O
of	of	O	O
these	these	O	O
symptoms	symptoms	O	O
,	,	O	O
probably	probably	O	O
caused	caused	O	O
by	by	O	O
the	the	O	O
vasodilating	vasodilating	O	O
effect	effect	O	O
of	of	O	O
the	the	O	O
two	two	O	O
agents	agents	O	O
,	,	O	O
were	were	O	O
of	of	O	O
mild	mild	O	O
degree	degree	O	O
and	and	O	O
no	no	O	O
special	special	O	O
treatment	treatment	O	O
was	was	O	O
required	required	O	O
.	.	O	O

Intraplatelet	intraplatelet	O	O
cAMP	camp	O	O
content	content	O	O
was	was	O	O
gradually	gradually	O	O
but	but	O	O
significantly	significantly	O	O
increased	increased	O	O
to	to	O	O
9.84	9.84	O	O
+	+	O	O
/-	/-	O	O
4.59	4.59	O	O
pmol	pmol	O	O
per	per	O	O
10(9	10(9	O	O
)	)	O	O
platelets	platelets	O	O
at	at	O	O
day	day	O	O
14	14	O	O
in	in	O	O
comparison	comparison	O	O
with	with	O	O
the	the	O	O
initial	initial	O	O
value	value	O	O
(	(	O	O
6.87	6.87	O	O
+	+	O	O
/-	/-	O	O
2.25	2.25	O	O
pmol	pmol	O	O
)	)	O	O
.	.	O	O

The	the	O	O
platelet	platelet	O	O
aggregability	aggregability	O	O
was	was	O	O
significantly	significantly	O	O
suppressed	suppressed	O	O
at	at	O	O
various	various	O	O
time	time	O	O
intervals	intervals	O	O
but	but	O	O
no	no	O	O
additive	additive	O	O
or	or	O	O
synergistic	synergistic	O	O
inhibitory	inhibitory	O	O
effect	effect	O	O
by	by	O	O
the	the	O	O
combined	combined	O	O
administration	administration	O	O
was	was	O	O
noted	noted	O	O
.	.	O	O

In	in	O	O
conclusion	conclusion	O	O
,	,	O	O
the	the	O	O
combined	combined	O	O
administration	administration	O	O
of	of	O	O
BPT/CLZ	bpt/clz	O	O
is	is	O	O
safe	safe	O	O
at	at	O	O
doses	doses	O	O
used	used	O	O
in	in	O	O
the	the	O	O
study	study	O	O
,	,	O	O
though	though	O	O
the	the	O	O
beneficial	beneficial	O	O
clinical	clinical	O	O
effect	effect	O	O
of	of	O	O
the	the	O	O
combined	combined	O	O
administration	administration	O	O
has	has	O	O
yet	yet	O	O
to	to	O	O
be	be	O	O
elucidated	elucidated	O	O
.	.	O	O

